In connection with the implementation by the Ordering Party of the project entitled “Use of matrix metalloproteinase inhibitor to develop an innovative therapy of preventing the development of post-traumatic and post-stroke epilepsy” /POIR.01.01.01-00-0235/20-00/ within Measure 1.1. R&D projects of enterprises, Submeasure 1.1.1 Industrial research and development work implemented by enterprises, co-financed by the European Regional Development Fund, and also in connection with the obligation to apply the principle of competitiveness,
Pikralida sp. z o.o. invites you to submit offers for the clinical trial monitoring conducting of the early phase clinical trial in healthy volunteers for molecule PKL-021 and auditing site and bioanalytical laboratory on behalf of the Sponsor in accordance with the principles of Good Clinical Practice (GCP) and Good Clinical Laboratory Practice (GCLP).
In connection with the questions from bidders regarding the description of the subject of the contract, we inform you that the deadline for concluding the offer has remained due until September 6, 2023.
Bids should be submitted electronically to the following e-mail address: pricing_offers@pikralida.eu or via the competitiveness database (link below), in person, by post or by courier to the address of our registered office (date of receipt shall be considered) by September 6, 2023, until: 11:59 pm.
The request for proposal No. 71/2022 and template documents have been published in the Competitiveness Database:
https://bazakonkurencyjnosci.funduszeeuropejskie.gov.pl/ogloszenia/170356